OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results.
OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 GuidanceCompany to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance SystemWARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”).
OrthoPediatrics Corp. Announces the Appointment of Kelly Fischer to its Board of DirectorsWARSAW, Ind., Aug. 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Kelly Fischer to its Board of Directors effective as of August 8, 2025. The appointment was made concurrent with the announcement of the retirement of Terry Schlotterback from the OrthoPediatrics Board of Directors, effective as of August 8, 2025.
OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue GuidanceSecond Quarter 2025 Revenue Surpasses $60 million for the First Time in Company History, and Increased Adjusted EBITDA by 58% year-over-year
OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple ClinicsWARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) division with multiple new clinics and entry into two new territories.
OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth ConferenceWARSAW, Ind., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 45th Canaccord Genuity Annual Growth Conference, held in Boston, MA.
OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First CaseWARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the US launch and first surgical case of the new 3P™ Pediatric Plating Platform™ Hip System, used to treat proximal femur fractures and deformities.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 5, 2025WARSAW, Ind., July 22, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2025 financial results on August 5, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 5, 2025 at 4:30 p.m. ET to discuss the results.
Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® ProductsWARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a significant milestone in the ongoing Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study: more than 600 implants are now being observed across 300+ pediatric patients as part of this study.
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip SystemWARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company’s 5th FDA approval in 2025.
OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results.
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ SystemWARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children.
